Health TrialsbyHealthPanel

Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke

ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYi Yang

About this trial

The purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with a definitive clinical diagnosis of acute ischemic stroke;

Age≥18 years, regardless of sex；

Primary education level or higher; baseline MoCA score of 10-25 points;

Able to complete cognitive scale scoring;

Disqualifiers

Transient ischemic attack；

Patients who received emergency reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy) at onset;

Combined with other neurological diseases, such as neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Lewy body dementia, and frontotemporal dementia), optic neuritis, epilepsy, central nervous system infections (e.g., AIDS and syphilis), traumatic brain injury dementia, etc；

Currently using psychoactive medications (e.g., antidepressants) or anti-epileptic drugs, or if the time since their last use of these medications was less than 5 half-lives (per the pharmacokinetics of each specific medication; for drugs with unknown half-lives, a 1 month washout period was required)；

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ginkgo Biloba Extract

    Drug

    Ginkgo biloba extract 8 pills three times per day is administrated.

Treatment groups

356 Participants
are divided into 2 treatment groups
Group A: The ginkgo biloba extract groupExperimental treatment 1 intervention
Group B: The control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Changes of the Montreal Cognitive Assessment (MoCA) score

The MoCA scores in the 180 day of treatment minus baseline MoCA scores. MoCA scores range from 0 to 30, with higher MoCA scores indicating better cognitive function.

Time frame
180 days

Secondary outcomes

1

Changes of the Mini-Metal State Examination (MMSE) score

The MMSE scores in the 180 day of treatment minus baseline MMSE scores. MMSE scores range from 0 to 30, with higher MMSE scores indicating better cognitive function.

Time frame
180 days
2

the Montreal Cognitive Assessment (MoCA) score

MoCA scores range from 0 to 30, with higher MoCA scores indicating better cognitive function.

Time frame
180 days
3

the Mini-Metal State Examination (MMSE) score

MMSE scores range from 0 to 30, with higher MMSE scores indicating better cognitive function.

Time frame
180 days
4

the modified rankin scale (mRS) score

mRS Scores range from 0 to 6, with a higher mRS Score indicating a worse prognosis.

Time frame
90 days; 180 days

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yi Yang

Lead sponsor

The First Hospital of Jilin University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: